DIVIS LABORATORIES
|
The Current P/E Ratio of DIVIS LABORATORIES is 89.33.
| Share Price | ₹11,315.1 | Nov 11,2026 |
| Market Cap | ₹300,415.9 Cr | |
| Earnings-TTM | ₹3,363.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 89.33x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of DIVIS LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹300,415.9 Cr] as on Nov 11,2026
(/) Earnings [ ₹3,363.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 89.33x ]
Thus, for DIVIS LABORATORIES , the investors are currently willing to pay 89.33 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of DIVIS LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of DIVIS LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of DIVIS LABORATORIES
PE Ratio Performance Analysis for DIVIS LABORATORIES
- DIVIS LABORATORIES 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 53.73x.
- DIVIS LABORATORIES 's operated at median p/e ratio of 56.92x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, DIVIS LABORATORIES 's p/e ratio peaked in Mar2025 at 69.83x.
- DIVIS LABORATORIES 's p/e ratio hit its five-year low in Mar2022 of 39.49x.
How does DIVIS LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| DIVIS LABORATORIES | 3,363.00 | 89.33 | 300,415.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 41.22 | 454,914.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 86.31 | 181,169.0 |
| CIPLA LTD | 2,868.29 | 39.91 | 114,478.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 41.65 | 114,933.0 |
| MANKIND PHARMA LTD | 2,249.69 | 48.78 | 109,746.0 |
| LUPIN LTD | 5,221.47 | 17.70 | 92,418.9 |
| ZYDUS LIFESCIENCES LTD | 4,159.00 | 28.54 | 118,713.0 |
| AUROBINDO PHARMA LTD | 3,993.05 | 26.30 | 105,006.0 |
| LAURUS LABS LTD | 1,333.75 | 98.64 | 131,566.0 |
| BIOCON LTD | 340.30 | 176.19 | 59,956.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs DIVIS LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.70x |
| Max industry PE | 176.19x |
| Median industry PE | 41.65x |
| Average industry PE | 63.14x |
You may also like the below Video Courses